CA2429059A1 - Coated medical devices for the prevention and treatment of vascular disease - Google Patents
Coated medical devices for the prevention and treatment of vascular disease Download PDFInfo
- Publication number
- CA2429059A1 CA2429059A1 CA 2429059 CA2429059A CA2429059A1 CA 2429059 A1 CA2429059 A1 CA 2429059A1 CA 2429059 CA2429059 CA 2429059 CA 2429059 A CA2429059 A CA 2429059A CA 2429059 A1 CA2429059 A1 CA 2429059A1
- Authority
- CA
- Canada
- Prior art keywords
- compounds
- medical device
- intraluminal medical
- prevention
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002265 prevention Effects 0.000 title claims abstract 12
- 208000019553 vascular disease Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract 34
- 238000012377 drug delivery Methods 0.000 claims abstract 12
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims abstract 9
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims abstract 9
- 229960002930 sirolimus Drugs 0.000 claims abstract 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract 4
- 230000001225 therapeutic effect Effects 0.000 claims 12
- 230000003902 lesion Effects 0.000 claims 11
- 208000037803 restenosis Diseases 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 239000011248 coating agent Substances 0.000 claims 6
- 238000000576 coating method Methods 0.000 claims 6
- 229920000642 polymer Polymers 0.000 claims 4
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 claims 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 2
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 claims 2
- 239000000039 congener Substances 0.000 claims 2
- 230000001086 cytosolic effect Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000035515 penetration Effects 0.000 claims 2
- 230000000144 pharmacologic effect Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 238000002586 coronary angiography Methods 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 231100000057 systemic toxicity Toxicity 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local delivery of the drugs or agents provides for increased effectiveness and lower systemic toxicity.
Claims (21)
1. A method for the prevention of target lesion restenosis comprising the controlled delivery, by a profiled release from an intraluminal medical device, of one or more compounds in therapeutic dosage amounts.
2. The method for the prevention of target lesion restenosis according to Claim 1, wherein the profiled release from an intraluminal medical device of one or more compounds comprises:
coating a first portion of the stent with a first concentration of the one or more compounds in therapeutic dosage amounts; and coating a second portion of the stent with a second concentration of the one or more compounds in therapeutic dosage amounts, wherein the second concentration is greater than the first concentration.
coating a first portion of the stent with a first concentration of the one or more compounds in therapeutic dosage amounts; and coating a second portion of the stent with a second concentration of the one or more compounds in therapeutic dosage amounts, wherein the second concentration is greater than the first concentration.
3. The method for the prevention of target lesion restenosis according to Claim 2, wherein the one or more compounds comprises rapamycin.
4. The method for the prevention of target lesion restenosis according to Claim 1, wherein the one or more compounds comprises rapamycin.
5. The method for the prevention of target lesion restenosis according to Claim 1, wherein the one or more compounds comprises analogs, derivatives and congeners that bind a high-affinity cytosolic protein, FKBP12, and possesses the same pharmacologic properties as rapamycin.
6. The method for the prevention of target lesion restenosis according to Claim 1, wherein the profiled release from an intraluminal medical device of one or more compounds comprises:
coating a first portion of the stent with a first concentration of the one or more compounds in therapeutic dosage amounts; and coating a second portion of the stent with a second concentration of another of the one or more compounds in therapeutic dosage amounts.
coating a first portion of the stent with a first concentration of the one or more compounds in therapeutic dosage amounts; and coating a second portion of the stent with a second concentration of another of the one or more compounds in therapeutic dosage amounts.
7. The method for the prevention of target lesion restenosis according to Claim 6, wherein the one or more compounds comprises rapamycin.
8. The method for the prevention of target lesion restenosis according to Claim 7, wherein the another of the one or more compounds comprises a high solubility inhibitor of the mammalin Target of Rapamycin.
9. The method for the prevention of target lesion restenosis according to Claim 1, further comprising adding an agent to enhance tissue penetration of the one or more compounds.
10. The method for the prevention of target lesion restenosis according to Claim 1, wherein the profiled release from an intraluminal medical device of one or more compounds comprises:
coating a first portion of the stent with a first mass of the one or more compounds in therapeutic dosage amounts in combination with a polymer; and coating a second portion of the stent with a second mass of the one or more compounds in therapeutic dosage amounts in combination with a polymer, wherein the second mass is greater than the first mass.
coating a first portion of the stent with a first mass of the one or more compounds in therapeutic dosage amounts in combination with a polymer; and coating a second portion of the stent with a second mass of the one or more compounds in therapeutic dosage amounts in combination with a polymer, wherein the second mass is greater than the first mass.
11. A drug delivery device comprising:
an intraluminal medical device; and a therapeutic dosage of one or more compounds releasably affixed, in a predetermined profile, to the intraluminal medical device for the treatment of target lesion restenosis.
an intraluminal medical device; and a therapeutic dosage of one or more compounds releasably affixed, in a predetermined profile, to the intraluminal medical device for the treatment of target lesion restenosis.
12. Drug delivery device according to Claim 11, wherein the intraluminal medical device comprises a stent.
13. The drug delivery device according to Claim 11, wherein the one or more compounds comprises rapamycin.
14. The drug delivery device according to Claim 11, wherein the one or more compounds comprises analogs, derivatives and congeners that bind a high-affinity cytosolic protein, FKBP12, and possesses the same pharmacologic properties as rapamycin.
15. The drug delivery device according to Claim 11, wherein the therapeutic dosage of one or more compounds releasably affixed, in a predetermined profile, to the intraluminal medical device comprises:
a first concentration of the one or more compounds affixed to a first portion of the intraluminal medical device; and a second concentration of the one or more compounds affixed to a second portion of the intraluminal medical device, wherein the second concentration is greater than the first concentration.
a first concentration of the one or more compounds affixed to a first portion of the intraluminal medical device; and a second concentration of the one or more compounds affixed to a second portion of the intraluminal medical device, wherein the second concentration is greater than the first concentration.
16. The drug delivery device according to Claim 15, wherein the one or more compounds comprises rapamycin.
17. The drug delivery device according to Claim 11, wherein the therapeutic dosage of one or more compounds releasably affixed, in a predetermined profile, to the intraluminal medical device comprises:
a first concentration of the one or more compounds affixed to a first portion of the intraluminal medical device; and a second concentration of another of one or more compounds affixed to a second portion of the intraluminal medical device.
a first concentration of the one or more compounds affixed to a first portion of the intraluminal medical device; and a second concentration of another of one or more compounds affixed to a second portion of the intraluminal medical device.
18. The drug delivery device according to Claim 17, wherein the one or more compounds comprises rapamycin.
19. The drug delivery device according to Claim 17, wherein the another of the one or more compounds comprises a high solubility inhibitor of the mammalian Target of Rapamycin.
20. The drug delivery device according to Claim 11, further comprising an agent for enhancing tissue penetration of the one or more compounds incorporated into the therapeutic dosage of one or more compounds releasably affixed in a predetermined profile to the intraluminal medical device.
21. The drug delivery device according to Claim 11, wherein the therapeutic dosage of one or more compounds releasably affixed, in a predetermined profile, to the intraluminal medical device comprises:
a first mass of the one or more compounds in combination with a polymer affixed to a first portion of the intraluminal medical device; and a second mass of the one or more compounds in combination with a polymer affixed to a second portion of the intraluminal medical device, the second mass is greater than the first mass.
a first mass of the one or more compounds in combination with a polymer affixed to a first portion of the intraluminal medical device; and a second mass of the one or more compounds in combination with a polymer affixed to a second portion of the intraluminal medical device, the second mass is greater than the first mass.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38198602P | 2002-05-20 | 2002-05-20 | |
| US60/381,986 | 2002-05-20 | ||
| US10/431,059 US7419678B2 (en) | 2000-05-12 | 2003-05-07 | Coated medical devices for the prevention and treatment of vascular disease |
| US10/431,059 | 2003-05-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2429059A1 true CA2429059A1 (en) | 2003-11-20 |
| CA2429059C CA2429059C (en) | 2011-10-25 |
Family
ID=29584344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2429059A Expired - Lifetime CA2429059C (en) | 2002-05-20 | 2003-05-20 | Coated medical devices for the prevention and treatment of vascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2429059C (en) |
-
2003
- 2003-05-20 CA CA2429059A patent/CA2429059C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2429059C (en) | 2011-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2408838A1 (en) | Drug/drug delivery systems for the prevention and treatment of vascular disease | |
| MXPA03004512A (en) | Coated medical devices for the prevention and treatment of vascular disease. | |
| CA2425696C (en) | Coated medical devices for the treatment of vascular disease | |
| EP1663339B1 (en) | Endoluminal prosthesis comprising a therapeutic agent | |
| Cremers et al. | Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter | |
| US8541014B2 (en) | Gamma-tocopherol therapy for restenosis prevention | |
| AU2001262957B2 (en) | Drug combinations useful for prevention of restenosis | |
| AU2001262957A1 (en) | Drug combinations useful for prevention of restenosis | |
| CA2490170A1 (en) | Local vascular delivery of trichostatin a alone or in combination with sirolimus to prevent restenosis following vascular injury | |
| EP1087801A1 (en) | Topoisomerase inhibitors for prevention of restenosis | |
| JP2005531332A (en) | Hormone-coated stent to prevent stenosis or atherosclerosis | |
| CA2502146A1 (en) | Solution formulations of sirolimus and its analogs for cad treatment | |
| CN101543659A (en) | Local vascular delivery system of probucol alone or in combination with sirolimus | |
| Grube et al. | Drug eluting stents: initial experiences | |
| Waksman | Drug-eluting stents: From bench to bed | |
| CN106310395A (en) | Composite drug-loading stent and preparation method thereof | |
| Windecker et al. | Sirolimus eluting stent: a new era in interventional cardiology? | |
| CA2429059A1 (en) | Coated medical devices for the prevention and treatment of vascular disease | |
| Raja | Drug-eluting stents: is it the beginning of the end for coronary artery bypass surgery? | |
| CN1306917C (en) | Scaffold for preventing/treating intravascular re-stricture by compound action mechanism | |
| Raja | Drug-Eluting Stents: The Myth, The Reality. | |
| Kiesz et al. | Local delivery of low molecular weight heparins | |
| Voudris | Drug-Eluting Stents in Coronary Interventions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20230523 |